TY - CHAP M1 - Book, Section TI - Anticoagulation/Venous Thromboembolism A1 - Sassenrath, Kimberly A1 - Phillips, Beth Bryles A2 - Sutton, S. Scott PY - 2020 T2 - McGraw Hill’s NAPLEX® Review Guide, 4e AB - Venous thromboembolism (VTE) is a common and serious disorder characterized by pathologic blood clot formation that includes deep vein thrombosis (DVT) and pulmonary embolism (PE). The balance between hemostasis (normal cessation of bleeding) and thrombosis is a sensitive process influenced by genetics, concomitant medical conditions, and other risk factors. Three primary determinants of thromboembolism include venous stasis (eg, immobility or paralysis), vascular wall injury (eg, surgery or trauma), and hypercoagulability (eg, thrombophilia, cancer, pregnancy, genetics). Classic symptoms of a DVT include unilateral pain, swelling, erythema, and tenderness usually of the lower extremity; although some patients may be symptom-free. Compression ultrasound is typically used to diagnose a DVT. The symptoms of a PE are nonspecific and may include chest pain, shortness of breath, tachypnea, dyspnea, and hemoptysis. Most PEs originate from a DVT. The diagnosis of a PE is made by the presence of symptoms in conjunction with findings on computed tomography (CT) or a ventilation-perfusion (V/Q) scan. Medical work-up of patients presenting with VTE include determination of risk factors for VTE. Certain risk factors are reversible (eg, estrogen use, recent orthopedic surgery, smoking, prolonged immobility) and may be eliminated over time. The presence of irreversible or continuing risk factors (eg, cancer, thrombophilia, previous history of VTE) requires longer or an extended duration of therapy. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/04/19 UR - accesspharmacy.mhmedical.com/content.aspx?aid=1179733116 ER -